Arab Finance: Egyptian International Pharmaceutical Industries Company (EIPICO) posted a 30.14% year-on-year (YoY) decline in consolidated net profits attributable to the holding company for the first nine months of 2026, according to financial statements filed to the Egyptian Exchange (EGX) on November 15.
The company's consolidated net profit excluding minority interest amounted to EGP 792.973 million, down from EGP 1.135 billion in the same period a year earlier.
Consolidated net revenue rose 3.22% YoY to EGP 7.389 billion in the January-September period of 2026, compared to EGP 7.158 billion a year earlier.
Meanwhile, the company recorded a 39.33% YoY decline in standalone net profit after tax to EGP 535.659 million, down from EGP 882.850 million in the corresponding period of 2025.
Founded in 1980, the pharmaceutical company currently exports to over 65 countries worldwide, including European, African, Asian, Latin American, and Commonwealth countries.
